You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

List of Excipients in Branded Drug ADEFOVIR DIPIVOXIL


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing ADEFOVIR DIPIVOXIL

Excipient Strategy and Commercial Opportunities for Adefovir Dipivoxil

Last updated: March 2, 2026

What are the key excipient considerations for Adefovir Dipivoxil?

Adefovir Dipivoxil is an oral antiviral agent used in the treatment of chronic hepatitis B. Its formulation requires excipients that ensure stability, bioavailability, and patient acceptability. The drug's chemical properties dictate specific excipient choices.

Core excipient roles:

  • Fillers/diluents: Microcrystalline cellulose, lactose monohydrate. Maintain consistent tablet weight and aid in compression.
  • Disintegrants: Crosscarmellose sodium, croscarmellose sodium. Promote rapid breakdown in gastrointestinal fluids.
  • Binders: Povidone (PVP K30). Ensure tablet cohesion.
  • Lubricants: Magnesium stearate. Facilitate manufacturing flow.
  • Coatings: Opadry or similar film coatings for masking taste and protecting from moisture.

Stability considerations:

Adefovir Dipivoxil is sensitive to moisture and temperature. Excipients must mitigate hydrolysis and degradation. Hydroxypropyl methylcellulose (HPMC) and ethylcellulose coatings are tested for moisture barriers.

What are the formulation challenges and innovative strategies?

  • Moisture sensitivity: Use of moisture-resistant coatings and desiccant packaging.
  • Bioavailability: Lipophilic excipients, such as stearates, enhance dissolution.
  • Taste masking: Use of polymer coatings and flavoring agents.

What are the commercial opportunities associated with excipient innovation?

Differentiation and patentability

Novel excipient combinations or coating techniques can create formulation patents, extending product lifecycle and market exclusivity. For example, developing a controlled-release matrix using hypromellose or ethylcellulose can allow dosing flexibility and improve adherence.

Cost optimization opportunities

Bulk purchasing of common excipients like microcrystalline cellulose and lactose reduces cost. Switching to lower-cost, functionally equivalent excipients can improve margins.

Patient compliance and branding

Taste-masked, palatable formulations and once-daily dosing regimens improve adherence. Custom packaging and coatings for fixed-dose combinations enhance brand differentiation.

Regulatory advantages

Establishing stable, well-characterized excipient profiles simplifies submission processes. Using excipients with documented safety profiles can reduce regulatory review times.

How does excipient choice impact the market potential?

  • Product stability: Extends shelf life, reduces waste, and improves supply chain reliability.
  • Manufacturing efficiency: Simplifies scale-up and lowers production costs.
  • Patient acceptance: Increases adherence, impacting treatment outcomes and overall market share.
  • Regulatory compliance: Facilitates faster time-to-market with approved formulations.

What partnership and supply chain strategies are relevant?

  • Collaborate with excipient suppliers offering high-quality, regulatory-compliant materials.
  • Engage with formulation R&D specialists to develop innovative excipient systems.
  • Adopt flexible supply chain models to adapt to fluctuating raw material costs.

Summary

Adefovir Dipivoxil formulation hinges on selecting excipients that enhance stability, bioavailability, and patient acceptability. Innovative excipient strategies such as controlled-release matrices, taste masking, and moisture barriers open opportunities for patenting, cost savings, and market differentiation. Leveraging these approaches supports long-term commercial success.

Key Takeaways

  • Excipient selection directly impacts drug stability, efficacy, and patient adherence.
  • Innovative excipient systems enable formulation patenting and product differentiation.
  • Cost-effective sourcing and formulation optimization can improve margins.
  • Stability and manufacturability strategies reduce supply risks and regulatory hurdles.
  • Expanding formulation capabilities supports market growth and lifecycle management.

FAQs

  1. What excipients are typically used in Adefovir Dipivoxil formulations?
    Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone, magnesium stearate, and film-coating agents like Opadry.

  2. How can excipient innovation extend the product lifecycle?
    By enabling new delivery formats (controlled release, taste masking), which can be patented and marketed, delaying generic competition.

  3. What are the main challenges in formulating Adefovir Dipivoxil?
    Stability under typical manufacturing and storage conditions, moisture sensitivity, and ensuring bioavailability.

  4. Can novel excipients improve patient adherence?
    Yes, through taste masking, reduced dosing frequency, and improved tolerability.

  5. How do regulatory considerations influence excipient choices?
    Using excipients with established safety profiles simplifies approval and reduces review times.


References

[1] Food and Drug Administration. (2022). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency. (2021). Reflection paper on excipients used in oral medicines.
[3] Khurana, R., & Singh, R. (2020). Enhanced stability of antiviral formulations. Journal of Pharmaceutical Sciences, 109(4), 1320-1330.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.